Research Article | Open Access
Maria Malm, Kirsi Tamminen, Suvi Lappalainen, Timo Vesikari, Vesna Blazevic, "Rotavirus Recombinant VP6 Nanotubes Act as an Immunomodulator and Delivery Vehicle for Norovirus Virus-Like Particles", Journal of Immunology Research, vol. 2016, Article ID 9171632, 13 pages, 2016. https://doi.org/10.1155/2016/9171632
Rotavirus Recombinant VP6 Nanotubes Act as an Immunomodulator and Delivery Vehicle for Norovirus Virus-Like Particles
We have recently shown that tubular form of rotavirus (RV) recombinant VP6 protein has an in vivo adjuvant effect on the immunogenicity of norovirus (NoV) virus-like particle (VLP) vaccine candidate. In here, we investigated in vitro effect of VP6 on antigen presenting cell (APC) activation and maturation and whether VP6 facilitates NoV VLP uptake by these APCs. Mouse macrophage cell line RAW 264.7 and dendritic cell line JAWSII were used as model APCs. Internalization of VP6, cell surface expression of CD40, CD80, CD86, and major histocompatibility class II molecules, and cytokine and chemokine production were analyzed. VP6 nanotubes were efficiently internalized by APCs. VP6 upregulated the expression of cell surface activation and maturation molecules and induced secretion of several proinflammatory cytokines and chemokines. The mechanism of VP6 action was shown to be partially dependent on lipid raft-mediated endocytic pathway as shown by methyl-β-cyclodextrin inhibition on tumor necrosis factor α secretion. These findings add to the understanding of mechanism by which VP6 exerts its immunostimulatory and immunomodulatory actions and further support its use as a part of nonlive RV-NoV combination vaccine.
Noroviruses (NoVs) and rotaviruses (RVs) are the major causative agents of pediatric acute gastroenteritis (AGE) in children worldwide. There is no licensed vaccine for NoV available, and despite efficacious live RV vaccines currently in use , there is a need  for nonlive RV vaccines that could be safer , more affordable, and more efficacious in developing countries [4–6]. Our group has developed a subunit combination vaccine candidate against NoV and RV gastroenteritis, consisting of NoV virus-like particles (VLPs) and RV VP6, aiming to confer protection from both leading etiological agents of severe AGE [7–9].
The double-stranded (ds) RNA genome of triple-layered RV particle is surrounded by core protein VP2 . The outermost layer, composed of VP7 capsid glycoprotein and the spike protein VP4, contains most epitopes for RV neutralizing antibody interaction . The intermediate layer is formed by the major internal structural protein VP6 that represents 51% of the virion mass . VP6 trimers are organized into hexagons and packed into higher order structures, for example, nanotubes, nanospheres, or sheets when expressed in vitro in baculovirus (BV) or bacterial expression systems [12–16]. The variable morphology of polymeric VP6 protein expressed in vitro depends on biochemical composition, mainly on pH and ionic strength .
Recombinant VP6 has been considered as a nonlive next generation vaccine candidate against RV by us and others, being the most abundant, highly conserved, and immunogenic RV protein [2, 7, 8, 18]. B-cell-mediated immune responses, especially IgA seroconversion following RV vaccination and natural infection, are mostly directed against VP6 . Even though the inner capsid protein VP6 cannot elicit classical neutralizing antibodies, it induced heterotypic protective immunity against live RV challenge in mice that correlated with postchallenge VP6-specific serum IgA . VP6-specific polymeric IgA inhibits RV replication intracellularly during IgA transcytosis, a phenomenon termed intracellular neutralization [21–23].
We have recently reported that VP6 protein provides dose sparing effect on NoV VLPs in vivo and acts as both Th1 and Th2 type adjuvant on immune response induced by NoV VLPs . Other investigators have shown that when VP6 is used as an antigen carrier or delivery platform for foreign antigens, the response to the antigen was improved [25, 26]; however, the mechanism was not investigated. Particulate nature and characteristics of an antigen, such as size, shape, surface charge, and receptor interactions, are generally considered important for antigen presenting cell (APC) targeting . Moreover, the antigen size influences development and quality of immune responses [28, 29]. Even though VP6 nanotubes and RV double-layered (dl) 2/6-VLPs have been shown to be equally immunogenic in vivo , there have also been indications of improved uptake of VP6 nanotubes compared to spherical forms of RV dlVLP .
We hypothesized that due to their size and morphology VP6 nanotubes may be potent inducers of APC activation and maturation. APCs are known to be critical for initiating and modulating antigen-specific immune responses [32, 33] and therefore are likely to have a key role in VP6 exerted adjuvant effect [24, 31]. In here, we investigated the effect of VP6 nanotubes on two commonly used APC lines, RAW 264.7 macrophages and JAWSII immature dendritic cells (DCs), aiming to improve understanding of the immunostimulatory and immunomodulatory mechanism of VP6 oligomeric protein.
2. Materials and Methods
2.1. Cell Lines, Viruses, and Culture Conditions
Adherent murine immortalized RAW 264.7 macrophage cell line, originating from blood monocyte/macrophages (H-2d) (Cat. TIB71), and JAWSII immature DCs, derived from bone marrow of H-2b C57BL/6 p53-knockout mouse (Cat. CRL-11904) , were obtained from the American Type Culture Collection (ATCC®, Manassas, VA). The cells were grown at 37°C in a 5% CO2 air humidified atmosphere and used for the treatments after at least 5 but less than 20 passages in our laboratory. RAW 264.7 cells were cultured in Dulbecco’s modified Eagle’s minimum essential medium (DMEM, Cat. D6546), supplemented with heat inactivated 10% fetal bovine serum (FBS, Cat. F9665), 100 units/mL penicillin, 100 μg/mL streptomycin (Cat. P0781), and 2 mM L-glutamine (Cat. G7513) (all from Sigma, St. Louis, MO). The JAWSII cells were maintained in minimum essential medium Eagle, alpha minimum essential medium (αMEM) supplemented with ribonucleosides, deoxyribonucleosides (Cat. M8042, Sigma), 1 mM sodium pyruvate (Cat. S8636, Sigma), 20% FBS, 4 mM L-glutamine, and 5 ng/mL recombinant murine granulocyte-macrophage colony-stimulating factor (GM-CSF, Cat. 415ML-010, R&D Systems, Inc.). Human epithelial colorectal adenocarcinoma cell line Caco-2 (ATCC, Cat. HTB-37) was used for internalization studies. Adherent Caco-2 cell line was cultured in a complete culture medium consisting of DMEM medium, 10% FBS, 100 units/mL penicillin, and 100 μg/mL streptomycin. Caco-2 cells were subcultured when they reached ~80% confluency and were not allowed to form tight monolayer or to differentiate before being used for the internalization analyses. Human RV strain Wa (G1P1A ) was propagated in fetal rhesus monkey kidney (MA104) cells as described elsewhere .
2.2. Recombinant Proteins Production and Purification
Human RV VP6 protein (database accession number GQ477131) and NoV GII.4 (reference strain accession number AF080551) VLPs were produced in a BV-insect cell expression system according to the previously described procedures [7, 8, 35]. The proteins were highly purified with demanding multistep chromatographic procedures  and the concentration, purity, integrity, and morphology of the proteins were verified as described in detail elsewhere [7, 24]. In brief, Pierce BCA protein assay (Thermo Scientific, Cat. 23227) was used for quantification of the total protein. The integrity of RV VP6 nanotubes (Figure 1(a)), trimeric VP6 (Figure 1(b)), and NoV GII.4 VLPs (Figure 1(c)) was verified under electron microscopy (EM). The purity was confirmed by Quant-it dsDNA Broad-Range Assay Kit (Invitrogen, Cat. Q33120; <10 ng dsDNA/10 μg of protein) and sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and densitometric analysis after silver staining (PageSilver™ silver staining kit, Fermentas, Cat. K0681) (data not shown). Infectious BV and endotoxin level were determined with BacPAK™ RapidTiter Kit (Clontech Laboratories, Cat. 631406; 0 pfu live BV/mL) and Limulus Amebocyte Lysate assay (Lonza, Cat. 244 N184-25; <0.1 endotoxin units/100 μg of protein). Crude purified VP6 preparation containing impurities related to the expression system, for example, residual BVs (106 plaque forming units/mL), was used in parallel with pure VP6 in internalization inhibition experiments as described below. The proportion of VP6 in impure VP6 preparation was calculated after the densitometric analysis of PAGE with AlphaEase® FC Software (Alpha Innotech, San Leandro, CA), as described previously .
2.3. Internalization of RV VP6, RV Wa, and GII.4 VLPs by Cell Lines
Uptake of RV VP6 nanotubes and RV Wa was tested in mouse RAW 264.7 macrophages, JAWSII DCs, and human colorectal epithelial Caco-2 cell lines. Each cell line was plated to cell-culture treated multidish wells and was allowed to attach overnight in the cell-type-specific culture medium. The culture medium was replaced with the medium containing 100 μg/mL of highly purified VP6 nanotubes, 1 : 10 diluted RV Wa, or fresh culture medium (for untreated control cells). After the incubation period of 4 h for RAW 264.7 cells only or 24 h for all three cell types, the cells were harvested and supernatants collected and stored at −80°C for cytokine analysis. The VP6 uptake was analyzed by intracellular staining and flow cytometry as described below.
The internalization of NoV GII.4 VLPs and cointernalization of GII.4 VLPs with RV VP6 nanotubes were carried out using the RAW 264.7 cells and 24 h incubation. Cells were pulsed with 100 μg/mL GII.4 alone or 100 μg/mL of GII.4 combined with 100 μg/mL of VP6. The internalization of GII.4 VLPs was analyzed by intracellular staining of NoV VLP and flow cytometry.
2.4. Macrophage and DC Activation and Maturation Analysis
VP6 mediated activation and maturation were explored by determining the change in the expression of cell surface markers and upregulation of cytokine secretion. After overnight incubation of RAW or JAWSII cells on the plates, the cell-culture medium was changed and cells were exposed to RV VP6 nanotubes (10 μg/mL or 50 μg/mL), trimeric (denatured) VP6 (10 μg/mL or 50 μg/mL), GII.4 VLPs (10 μg/mL or 50 μg/mL), RV Wa (1 : 10 dilution), or 1 μg/mL of bacterial lipopolysaccharide (LPS) (Cat. L6143, Sigma) and incubated further for 24 h or 48 h. Supernatants of all cultures were collected, centrifuged, and stored at −80° until cytokine analysis. The cell surface expression of costimulatory and maturation markers CD80, CD86, CD40, and major histocompatibility complex (MHC) class II molecules was analyzed by flow cytometry as described below.
2.5. Inhibition of RV VP6 Internalization
Pharmacological internalization inhibitors methyl-β-cyclodextrin (MβCD, Cat. C4555), chloroquine diphosphate salt (Cat. C6628), and cytochalasin D from Zygosporium mansonii (Cat. C2618) (all from Sigma) were employed. RAW cells were plated and allowed to attach before adding the inhibitors at predetermined nontoxic concentrations. Cells were preincubated in cell-culture medium supplemented with 15 μM chloroquine, 2 mM MβCD (without serum), or 2 μM cytochalasin D for 60 min before exposing cells to 50 μg/mL of VP6 nanotubes and incubating them further for 17 h. In addition, the concentration of 50 μg/mL of crude purified VP6 nanotubes containing impurities related to the expression system, for example, residual BVs, was used as a control.
2.6. Flow Cytometry Analysis
The cells were harvested and washed with cold PBS + 3% FBS. Prior to staining or permeabilization the cells were blocked with rat anti-mouse CD16/CD32 (Fc Block, Clone 2.4G2, Becton Dickinson, San Jose, CA) on ice for 10 min followed by washing with PBS + 3% FBS. For intracellular staining of the internalized RV VP6 or NoV GII.4 VLPs, the BD Cytofix/Cytoperm Plus kit (Becton Dickinson, San Jose, CA) was used according to manufacturer’s instructions. For detection of VP6, permeabilized and fixed cells were stained intracellularly with rabbit polyclonal rotavirus group A antibody (Cat. GWB-459FC9, Genway Biotech Inc.) followed by fluorescein isothiocyanate- (FITC-) conjugated goat anti-rabbit Ig (BD Pharmingen). For GII.4 VLP staining, a human serum highly positive for anti-GII.4 NoV antibodies was used at 1 : 2000 dilution, followed by polyclonal anti-human IgG (Fc γ-specific) phycoerythrin (PE) conjugate (eBioscience) for detection. Internalization was examined by overlaying the histograms of treated and untreated cells and by comparing mean fluorescence intensity (MFI) of each population.
For the cell surface molecules expression analysis, RAW 264.7 cells were stained on ice for 30 min with anti-mouse monoclonal antibodies PerCP-Cy5.5-conjugated CD80 (16-10A1), PE-Cy7-conjugated CD86 (GL1), PE-conjugated CD40 (3/23), and Alexa Fluor 647-conjugated I-A/I-E (M5/114.15.2) (mouse MHC class II). BD CompBeads used for compensation and conjugated cell surface marker monoclonal antibodies were purchased from BD Biosciences.
The flow cytometry analyses were performed on a FACSCanto™ II (Becton Dickinson, San Jose, CA) flow cytometer, using the FACSDiva™ Version 6.1.3 software (Becton Dickinson). The data analysis was carried out with FlowJo software version 10 (Three Star Inc., San Carlos, CA).
2.7. Cytokine ELISAs
Quantities of tumor necrosis factor alpha (TNF-α), interleukin-6 (IL-6), and interferon-alpha (IFN-α) cytokines in RAW and JAWSII cell supernatants were determined by commercial enzyme-linked immunosorbent assay (ELISA) kits: mouse TNF-α DuoSet (Cat. DY410-05), mouse IL-6 DuoSet (Cat. DY406-05), and VeriKine mouse IFN alpha ELISA kit (Cat. 42120-1, PBL Assay Science) according to the manufacturers’ instructions. Victor2 1420 Multilabel Counter (Wallac, Perkin Elmer) plate reader was used for optical density reading (OD) of the plate. For each assay the background signal from the blank wells (wells without supernatant) was subtracted from all of the OD readings on the plate. Standard curves were plotted and used for calculating the cytokine concentration of each sample (pg/mL).
2.8. Cytokine Array
Cytokine antibody array was performed with a mouse cytokine array kit (Cat. ARY006, R&D Systems, Inc., MN) according to the manufacturer’s protocol. Briefly, RAW 264.7 cell-culture supernatants were collected after 24 h stimulation with 100 μg/mL VP6 nanotubes or left untreated. Supernatants were centrifuged and stored at −80°C until analyzed. The membranes precoated with 40 different cytokine/chemokine-specific capture antibodies were blocked and incubated with 1 : 5 diluted supernatants overnight at +4°C. After washing, the detection antibody cocktail was added for 30 min, followed by streptavidin-horseradish peroxidase and chemiluminescent detection reagent. The immunoblot images were captured and visualized using a Bio-Rad ChemiDoc™ MP system and the intensity of each spot in the captured images was analyzed using a ImageJ 1.50b software.
2.9. Statistical Analysis
Cytokine release (pg/mL) in ELISA was compared using Mann–Whitney test. The data were analyzed by IBM SPSS Statistics software version 22.0 and value of <0.05 was considered statistically significant.
3.1. Internalization of VP6 Nanotubes by Macrophages and Immature DC
After incubating RAW 264.7, JAWSII, or human colorectal epithelial Caco-2 cells with 100 μg/mL of VP6 or RV Wa, the entry of the RV protein was examined by flow cytometry and compared to cells incubated with culture medium only (untreated cells). VP6 nanotubes were shown to be internalized by macrophages (Figure 2(a)) and DC (Figure 2(b)) but not by Caco-2 epithelial cells (Figure 2(c)).
Within 24 h of incubation of RAW cells with VP6, the RV-specific intracellular staining increased by 202–256% (range of percent increase of MFI for three independent experiments) compared to untreated cells. A 120% increase was observed in RAW cells exposed to RV Wa (Figure 2(a)). VP6 entry to RAW cells was observed already at 4 h but at a much lower quantity than after 24 h (data not shown). VP6 was also internalized by JAWSII cells within 24 h incubation but less efficiently than by RAW macrophages (Figure 2(b)). Compared to untreated cells, VP6 treatment induced a moderate 49–60,9% increase in RV-specific intracellular staining. In contrast to these results, a control cell line for internalization, human colorectal epithelial Caco-2 cells highly susceptible to RV infection , did not take up VP6 alone, but a 282–311% increase in MFI was detected after RV Wa exposure (Figure 2(c)).
3.2. Activation and Maturation Phenotype of APCs Induced by VP6 Nanotubes
After 24 h and 48 h stimulation of RAW and JAWSII cells with 50 μg/mL of VP6 nanotubes, 1 : 10 diluted RV Wa, or 1 μg/mL of LPS, the change in the expression of cell surface molecules CD80, CD86, CD40, and MHC II was examined by flow cytometry. As shown in Figures 3(a) and 3(b), VP6 stimulation upregulated MFI of all four markers compared to untreated RAW cells already in 24 h, which further increased within 48 h. LPS, used as a positive control, upregulated strongly all markers already within 24 h as expected (Figure 3(b)). Viral control (RV Wa) also induced high surface marker upregulation similarly to LPS (Figures 3(a) and 3(b)). Similar pattern of cell surface molecules expression upregulation with all three stimuli was observed with JAWSII cells but the increases were not as prominent as with the RAW cells (data not shown).
3.3. Effect of VP6 on Proinflammatory Cytokines and Chemokine Secretion
After 24 h or 48 h incubation of RAW and JAWSII cells with VP6 nanotubes, GII.4 VLPs, nonpolymeric denatured VP6 (10 μg/mL and 50 μg/mL each protein), RV Wa, or LPS, supernatant was collected and TNF-α, IL-6, and IFN-α were quantified by ELISA (Figure 4(a)). Nonpolymeric trimeric VP6 lacking conformational structures (Figure 1(b)) was used as a control protein.
Both RAW and JAWSII cells secreted TNF-α in a dose-response manner after 10 and 50 μg/mL VP6 nanotube exposure (Figure 4(a)). However, GII.4 VLP did not induce considerable TNF-α in JAWS cells (74 ± 57 pg/mL, resp.) as did VP6 nanotubes at the same concentration (713 ± 296 pg/mL). TNF-α production was significantly higher in VP6 nanotube exposed cells in both RAW and JAWSII cells compared to untreated cells (). These two cell lines exhibited different cytokine expression profiles upon stimulation, the primary cytokine secreted by RAW cells being TNF-α, while JAWSII DCs produced higher quantities of IL-6 (Figure 4(a)). Interestingly, VP6 nanotubes and RV Wa induced similar TNF-α secretion in RAW cells (), but only VP6 stimulated significant production of TNF-α in JAWSII cells. A tubular structure of VP6 was essential for the stimulatory effect of the protein, as more TNF-α was secreted after exposing RAW cells to 10 μg/mL (1756 ± 135 pg/mL) or 50 μg/mL (9224 ± 1409 pg/mL) of VP6 nanotubes, compared to the equal concentrations of nonpolymeric VP6 control (411 ± 75 and 539 ± 14 pg/mL, resp.).
The constitutive IL-6 secretion by JAWSII cells was remarkably stimulated by VP6 nanotubes, whereas only subtle changes were detected in the supernatants of the cells incubated in the presence of GII.4 VLP (Figure 4(a)). RV Wa had a moderate effect on IL-6 secretion by JAWSII cells, whereas the positive control LPS elicited high IL-6 secretion. Only small quantities of IL-6 were produced by RAW cells stimulated with VP6 and RV Wa but not at all with GII.4 VLPs. As expected, antiviral cytokine IFN-α secretion was detected only after RV Wa stimulation in both cell lines but not when exposed to protein products or LPS.
The cytokine profile of RAW supernatant stimulated with 100 μg/mL VP6 for 24 h was further examined by cytokine array, indicating a strong activation of the cells (Figures 4(b) and 4(c)). Several cytokines and chemokines were upregulated (Figure 4(c)), including interferon gamma-inducible protein (IP-10) and macrophage inflammatory protein (MIP-) 1α and MIP-1β, when compared to supernatant of untreated cells (CM only). However, TNF-α, granulocyte-colony-stimulating factor (G-CSF), MIP-2, IL-1ra, and RANTES were only detected in VP6 stimulated cells. As IL-6 cytokine production by RAW cells at 24 h was not detected by ELISA (Figure 4(a)) and it was not detected by the cytokine array either, corroborating the findings (data not shown).
3.4. Effect of Chemical Inhibitors on Internalization and TNF-α Production
The effect of chemical inhibitors MβCD, cytochalasin D, and chloroquine on the VP6 nanotube internalization and VP6-induced TNF-α secretion by RAW 264.7 cells was investigated. Both highly purified VP6 nanotubes and the VP6 nanotubes known to contain BV-related impurities, which assumingly employ different entry pathways into the cells, were used in these experiments. After MβCD treatment, a 22 ± 11% decrease in TNF-α secretion was observed in RAW cells stimulated with pure VP6 (Figure 5), whereas MβCD showed an increasing effect (43 ± 2%) when impure VP6 was used. Other two chemical inhibitors, cytochalasin D and chloroquine, did not decrease TNF-α production in RAW cells induced by pure VP6 nanotubes. On the contrary, TNF-α production induced by impure VP6 was almost completely blocked (94 ± 0.1%) by chloroquine treatment (Figure 5), indicating that the two protein preparations have different stimulatory mechanism. This observation was further supported by ~26% inhibition of impure VP6 internalization by chloroquine treatment, while the internalization of pure VP6 did not significantly change with any of the treatments (data not shown).
3.5. Increased GII.4 VLP Uptake and APC Activation and Maturation by VP6 Nanotubes Codelivery
The coadministration of VP6 nanotubes with GII.4 VLPs improved uptake of GII.4 VLPs to RAW 264.7 cells (Figure 6(a)). When RAW cells were incubated for 24 h with 100 μg/mL GII.4 VLPs, 47% of the cells were positive for NoV GII.4 when analyzed by intracellular staining. Coadministration of GII.4 VLPs with VP6 nanotubes further increased the number of NoV-positive cells by 30% (from 47% to 61%, resp.). A twofold increase in TNF-α secretion was observed in cells incubated with GII.4 + VP6 combination (11490 ± 741 pg/mL), compared to GII.4 VLPs alone (5761 ± 922 pg/mL) (Figure 6(b)), indicating an additive effect of the two proteins on the cytokine secretion. Furthermore, improved maturation of RAW macrophages was achieved with coadministration, as illustrated in Figure 6(c). NoV GII.4 VLPs + VP6 upregulated cell surface molecules CD40, CD80, CD86, and MHC II expression compared to GII.4 VLPs alone. Interestingly, MHC II downregulation was repeatedly observed when incubating RAW cells with GII.4 VLPs only.
We have recently shown in vivo adjuvant effect of VP6 nanostructures on the immunogenicity of NoV VLPs , where coadministration of VP6 nanotubes with suboptimal doses of NoV GII.4 VLPs increased the level of type-specific and cross-reactive NoV-specific immune responses. Therefore, in the present work, we investigated the effect of VP6 on activation and maturation of mouse RAW 264.7 macrophages and JAWSII immature DCs. Macrophages and DCs are professional APCs with high endocytic capacity known to be central for mounting effective T- and B-cell immune responses to foreign antigens in vivo [37–40]. The results provide an insight into the mechanism of VP6 adjuvant action.
RAW and JAWSII cells were first tested for uptake of VP6 in vitro. Extremely pure recombinant VP6 nanotubes were efficiently internalized by the RAW macrophages and to less extent by JAWSII DCs. Human epithelial Caco-2 cells were used as a control cell line as, unlike APCs, they are not efficient in uptake of larger particles but are susceptible to human RV Wa infection . Accordingly, no significant uptake of VP6 was detected in Caco-2 cells, while RVs were readily internalized. These results are congruent with the report by Rodríguez et al. , who showed that VP6 nanotubes were favorable for macrophage uptake.
Along with being internalized by macrophages and immature DCs, VP6 nanotubes induced activation and maturation of APCs by upregulating cell surface costimulatory and antigen presenting molecules CD40, CD80, CD86, and MHC II. Signaling through CD80 and/or CD86 on mature APCs, which bind to CD28 on T cells [41, 42], is a key costimulatory pathway for antigen-specific T cell activation. A bacterial activator LPS, a toll-like receptor (TLR) 4 agonist, was used as a control stimulus, as it is well known that it induces activation of APCs, including RAW 264.7 cells [43, 44]. The RAW 264.7 and JAWSII activation state was also determined by release of broad panel of cytokines and chemokines. An increase in the expression pattern of cell activation markers following VP6 exposure was accompanied by increase in proinflammatory cytokine secretion, primarily TNF-α by RAW cells and IL-6 by JAWSII cells. In RAW cells, 50 μg/mL VP6 nanotubes induced TNF-α at a similar level to RV Wa and GII.4 VLPs stimulation. Interestingly, only VP6 nanotubes but not GII.4 VLPs or RV Wa stimulated remarkably high TNF-α and IL-6 response in JAWSII DCs. Consistent with this observation, Istrate et al.  reported that even if RV dlVLPs were internalized by DCs, they could not trigger their activation. A key proinflammatory cytokine, TNF-α, recruits and activates APCs at the site of inflammation (antigen delivery) and facilitates APC migration to the lymph nodes , thereby improving the antigen uptake and presentation to MHC I and MHC II restricted T cells. In addition, TNF-α and IL-6 have important roles in the generation of B-cell functions like proliferation and antibody secretion . Overall, quantification of TNF-α and IL-6 showed that VP6 nanotubes are more potent in inducing these cytokines than NoV VLPs or RV. In addition, a nonpolymeric VP6 protein was not able to induce cytokine secretion near to the VP6 nanotubes. These results underline the importance of intact high order tubular structure conformation of VP6 in activation of APCs.
Furthermore, changes in the levels of different cytokines and chemokines were evaluated in untreated or VP6 stimulated RAW 264.7 cells by cytokine array. The results suggested that VP6 induces multiple cytokines (TNF-α, G-CSF, and IL-1ra) and chemokines (IP-10, MIP-1β, MIP-2, and RANTES) secretion into the supernatants of stimulated cells. G-CSF is a multifunctional cytokine  that is required for modulating macrophage and DC responses  and T cell responses following antigen stimulation . RANTES, IP-10, IL-8, MIP-1β, and monocyte chemoattractant protein-1 (MCP-1) have been suggested to be the key host factors in gastrointestinal immunity during RV infection [50, 51].
Employing highly purified protein preparations is of high importance when investigating adjuvant properties of a protein, eliminating the immunostimulatory effect of impurities related to the protein expression system on APCs. The results with VLP preparations containing residual BV particles have strongly suggested that BV contaminants can trigger an innate immunity, inducing inflammatory cytokine production such as TNF-α, IL-6, and IFN-α [44, 52, 53]. Therefore, we tested RAW 264.7 and JAWSII cells for secretion of IFN-α, an antiviral cytokine induced upon live virus or virus-derived dsRNA stimulation of the cells through TLR3 [45, 53, 54]. Only RV Wa stimulation but not any other stimuli including highly purified VP6 nanotubes, GII.4 VLP, or LPS induced significant release of the cytokine by these cell lines showing that the recombinant proteins used to stimulate the APC in our assays were free of BV contamination.
The size from 0.2 μm to 1.5 μm and the morphology of VP6 nanotubes are favorable for macrophages and DC recognition and uptake resembling those of microorganisms [30, 31, 55]. Antigen acquisition by APCs is mediated by several uptake mechanisms such as receptor-mediated endocytosis, macropinocytosis, and phagocytosis, depending of the nature of the antigen [56–59]. Smaller particles (20–200 nm) are usually internalized via receptor-mediated endocytosis dependent on membrane clathrin or caveolin . Larger particles are taken up by macrophages, B cells, Langerhans cells, and DC, through receptor-independent macropinocytosis (>0.5 μm) or receptor-mediated phagocytosis (0.5–5 μm) . Bluetongue virus nonstructural NS1 protein tubular structures, which are similar in size (up to 1 μm long and app. 50 nm in diameter) and morphology to VP6 nanotubes, were suggested to be internalized by macrophages and DC via endocytosis and macropinocytosis . We used chemical inhibitors MβCD, chloroquine, and cytochalasin D to study the possible uptake and activation pathways of VP6 nanotubes . TNF-α secretion was used for evaluating inflammatory APC activation and impure VP6 preparation containing production related impurities, including BV, was included as a control. Our results indicated a difference in the mechanism of RAW 264.7 cells uptake and activation by the two RV VP6 protein preparations. MβCD treatment depletes cholesterol which is a reversible mechanism that inhibits the formation of cholesterol-rich microdomains termed lipid rafts  important in the lipid raft-mediated endocytosis. Interestingly, when pure VP6 nanotubes were used, MβCD partially inhibited TNF-α secretion (22%), whereas impure VP6-induced TNF-α secretion was blocked almost completely by clathrin-dependent endocytosis inhibitor chloroquine. In support to our findings, Rodríguez et al.  showed by fluorescent microscopy the inhibition of VP6 cellular entry by MβCD. Furthermore, Abe et al.  observed that treatment with chloroquine inhibited BV-induced innate immune system activation and TNF-α secretion through BV gp64-mediated membrane fusion and TLR9/MyD88-dependent pathway. Cytochalasin D, which inhibits actin-dependent cellular processes such as phagocytosis , was not observed to have an effect on TNF-α secretion or VP6 protein uptake, unlike the published results where BV expression system-derived human immunodeficiency virus VLPs entry to APCs was blocked . Altogether, the results with chemical inhibitors indicate that VP6 entry and activation of RAW cells require host cholesterol and may be partially mediated by lipid rafts. Due to the size range of VP6 nanotubes (~0.2–1.5 μm, ), several entry pathways are likely to be involved and reaching total blocking is challenging.
Adjuvants generally work to spare the dose of particular vaccine antigen, to broaden the immune responses, and to prolong the duration of the response. The results of this study support our earlier findings of VP6 adjuvant effect on NoV VLPs immunogenicity in vivo  and show that VP6 nanotubes are efficiently internalized by APCs and induce activation and maturation of APCs. Induction of proinflammatory cytokines and chemokines by VP6 stimulated APCs, as shown in here, indicates efficient activation of the innate immune system, a major mechanism of adjuvant action. A depo effect is yet another important mechanism of adjuvant action that facilitates and improves the uptake of antigens by APCs. In here, a 30% increase in NoV GII.4 VLP uptake by APCs was observed when NoV VLPs were codelivered with RV VP6, compared to GII.4 VLP alone. In addition, VP6 coadministration showed increased activation and maturation of APCs measured by TNF-α production and upregulation of cell surface markers expression compared to NoV VLPs alone. Moreover, the exposure of RAW cells to GII.4 VLPs caused downregulation of MHC II expression, which was corrected by addition of VP6. Finally, our results identify the mechanisms of VP6 adjuvant action in vitro. VP6 nanotubes activate and mature APCs and increase the uptake of NoV VLPs by the APC.
In the present study, we show that recombinant RV inner core capsid VP6 nanotubes are efficiently internalized by professional APCs probably by a clathrin-independent endocytosis pathway involving cholesterol-rich lipid rafts, but likely other internalization routes are also involved. Moreover, VP6 nanotubes efficiently activate and mature macrophages and DCs as shown by upregulation of costimulatory molecules and MHC II expression and release of inflammatory mediators such as TNF-α, thus augmenting the action of cells of both innate and adaptive immune system. Furthermore, VP6 nanotubes facilitate the APC uptake of codelivered antigen, NoV GII.4 VLPs. These results provide insights into the mechanism of adjuvant action of VP6 nanotubes and confirm the immunostimulatory and immunomodulatory potential of VP6 observed in vivo.
The authors declare that there are no competing interests regarding the publication of this paper.
UMN Pharma is acknowledged for producing chromatographically purified proteins. We gratefully acknowledge the technical assistance given by the laboratory personnel of the Vaccine Research Center of University of Tampere.
- T. Vesikari, “Rotavirus vaccination: a concise review,” Clinical Microbiology and Infection, vol. 18, supplement 5, pp. 57–63, 2012.
- R. L. Ward and M. M. McNeal, “VP6: a candidate rotavirus vaccine,” The Journal of Infectious Diseases, vol. 202, supplement 1, pp. S101–S107, 2010.
- M. M. Patel, D. Steele, J. R. Gentsch, J. Wecker, R. I. Glass, and U. D. Parashar, “Real-world impact of rotavirus vaccination,” Pediatric Infectious Disease Journal, vol. 30, no. 1, pp. S1–S5, 2011.
- J. Angel, M. A. Franco, and H. B. Greenberg, “Rotavirus immune responses and correlates of protection,” Current Opinion in Virology, vol. 2, no. 4, pp. 419–425, 2012.
- K. Zaman, D. D. Anh, J. C. Victor et al., “Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial,” The Lancet, vol. 376, no. 9741, pp. 615–623, 2010.
- S. A. Madhi, N. A. Cunliffe, D. Steele et al., “Effect of human rotavirus vaccine on severe diarrhea in African infants,” The New England Journal of Medicine, vol. 362, no. 4, pp. 289–298, 2010.
- V. Blazevic, S. Lappalainen, K. Nurminen, L. Huhti, and T. Vesikari, “Norovirus VLPs and rotavirus VP6 protein as combined vaccine for childhood gastroenteritis,” Vaccine, vol. 29, no. 45, pp. 8126–8133, 2011.
- K. Tamminen, S. Lappalainen, L. Huhti, T. Vesikari, and V. Blazevic, “Trivalent combination vaccine induces broad heterologous immune responses to norovirus and rotavirus in mice,” PLoS ONE, vol. 8, no. 7, article e70409, 2013.
- S. Lappalainen, A. R. Pastor, K. Tamminen et al., “Immune responses elicited against rotavirus middle layer protein VP6 inhibit viral replication in vitro and in vivo,” Human Vaccines & Immunotherapeutics, vol. 10, no. 7, pp. 2039–2047, 2014.
- B. V. V. Prasad, G. J. Wang, J. P. M. Clerx, and W. Chiu, “Three-dimensional structure of rotavirus,” Journal of Molecular Biology, vol. 199, no. 2, pp. 269–275, 1988.
- P. A. Offit and G. Blavat, “Identification of the two rotavirus genes determining neutralization specificities,” Journal of Virology, vol. 57, no. 1, pp. 376–378, 1986.
- M. K. Estes, “Rotaviruses,” in Fields Virology, D. M. Knipe, Ed., pp. 1917–1974, Lippincott Williams & Wilkins, Philadelphia, Pa, USA, 5th edition, 2007.
- M. K. Estes, S. E. Crawford, M. E. Penaranda et al., “Synthesis and immunogenicity of the rotavirus major capsid antigen using a baculovirus expression system,” Journal of Virology, vol. 61, no. 5, pp. 1488–1494, 1987.
- F. Bugli, V. Caprettini, M. Cacaci et al., “Synthesis and characterization of different immunogenic viral nanoconstructs from rotavirus VP6 inner capsid protein,” International Journal of Nanomedicine, vol. 9, no. 1, pp. 2727–2739, 2014.
- A. H.-C. Choi, M. Basu, M. M. McNeal, J. D. Clements, and R. L. Ward, “Antibody-independent protection against rotavirus infection of mice stimulated by intranasal immunization with chimeric VP4 or VP6 protein,” Journal of Virology, vol. 73, no. 9, pp. 7574–7581, 1999.
- A. Z. Kapikian, Y. Hoshino, and R. M. Chanock, “Reoviridae,” in Rotaviruses, B. N. Fields, D. M. Knipe, and P. M. Howley, Eds., chapter 55, pp. 2719–2769, Lippincott Williams & Wilkins, 4th edition, 2001.
- J. Lepault, I. Petitpas, I. Erk et al., “Structural polymorphism of the major capsid protein of rotavirus,” The EMBO Journal, vol. 20, no. 7, pp. 1498–1507, 2001.
- I. Schwartz-Cornil, Y. Benureau, H. Greenberg, B. A. Hendrickson, and J. Cohen, “Heterologous protection induced by the inner capsid proteins of rotavirus requires transcytosis of mucosal immunoglobulins,” Journal of Virology, vol. 76, no. 16, pp. 8110–8117, 2002.
- M. A. Franco, J. Angel, and H. B. Greenberg, “Immunity and correlates of protection for rotavirus vaccines,” Vaccine, vol. 24, no. 15, pp. 2718–2731, 2006.
- S. Lappalainen, A. R. Pastor, M. Malm et al., “Protection against live rotavirus challenge in mice induced by parenteral and mucosal delivery of VP6 subunit rotavirus vaccine,” Archives of Virology, vol. 160, no. 8, pp. 2075–2078, 2015.
- M. S. Aiyegbo, G. Sapparapu, B. W. Spiller et al., “Human rotavirus VP6-specific antibodies mediate intracellular neutralization by binding to a quaternary structure in the transcriptional pore,” PLoS ONE, vol. 8, no. 5, Article ID e61101, 2013.
- J. W. Burns, M. Siadat-Pajouh, A. A. Krishnaney, and H. B. Greenberg, “Protective effect of rotavirus VP6-specific IgA monoclonal antibodies that lack neutralizing activity,” Science, vol. 272, no. 5258, pp. 104–107, 1996.
- B. Corthésy, Y. Benureau, C. Perrier et al., “Rotavirus anti-VP6 secretory immunoglobulin A contributes to protection via intracellular neutralization but not via immune exclusion,” Journal of Virology, vol. 80, no. 21, pp. 10692–10699, 2006.
- V. Blazevic, M. Malm, D. Arinobu, S. Lappalainen, and T. Vesikari, “Rotavirus capsid VP6 protein acts as an adjuvant in vivo for norovirus virus-like particles in a combination vaccine,” Human Vaccines & Immunotherapeutics, vol. 12, no. 3, pp. 740–748, 2016.
- M. J. Redmond, H. B. Ohmann, H. P. A. Hughes et al., “Rotavirus particles function as immunological carriers for the delivery of peptides from infectious agents and endogenous proteins,” Molecular Immunology, vol. 28, no. 3, pp. 269–278, 1991.
- A. Peralta, P. Molinari, and O. Taboga, “Chimeric recombinant rotavirus-like particles as a vehicle for the display of heterologous epitopes,” Virology Journal, vol. 6, article 192, 2009.
- C. Foged, B. Brodin, S. Frokjaer, and A. Sundblad, “Particle size and surface charge affect particle uptake by human dendritic cells in an in vitro model,” International Journal of Pharmaceutics, vol. 298, no. 2, pp. 315–322, 2005.
- R. A. Benson, M. K. L. Macleod, B. G. Hale, A. Patakas, P. Garside, and J. M. Brewer, “Antigen presentation kinetics control T cell/dendritic cell interactions and follicular helper T cell generation in vivo,” eLife, vol. 4, Article ID e06994, 2015.
- S. D. Xiang, A. Scholzen, G. Minigo et al., “Pathogen recognition and development of particulate vaccines: does size matter?” Methods, vol. 40, no. 1, pp. 1–9, 2006.
- S. Lappalainen, K. Tamminen, T. Vesikari, and V. Blazevic, “Comparative immunogenicity in mice of rotavirus VP6 tubular structures and virus-like particles,” Human Vaccines and Immunotherapeutics, vol. 9, no. 9, pp. 1991–2001, 2013.
- M. Rodríguez, C. Wood, R. Sanchez-López, R. M. Castro-Acosta, O. T. Ramírez, and L. A. Palomares, “Understanding internalization of rotavirus VP6 nanotubes by cells: towards a recombinant vaccine,” Archives of Virology, vol. 159, no. 5, pp. 1005–1015, 2014.
- J. Banchereau and R. M. Steinman, “Dendritic cells and the control of immunity,” Nature, vol. 392, no. 6673, pp. 245–252, 1998.
- P. J. Murray and T. A. Wynn, “Protective and pathogenic functions of macrophage subsets,” Nature Reviews Immunology, vol. 11, no. 11, pp. 723–737, 2011.
- V. L. MacKay and E. E. Moore, “Inventors. AnonymousImmortalized dendritic cells,” US patent. 1997.
- L. Huhti, V. Blazevic, K. Nurminen, T. Koho, V. P. Hytönen, and T. Vesikari, “A comparison of methods for purification and concentration of norovirus GII-4 capsid virus-like particles,” Archives of Virology, vol. 155, no. 11, pp. 1855–1858, 2010.
- L. Svensson, B. B. Finlay, D. Bass, C.-H. von Bonsdorff, and H. B. Greenberg, “Symmetric infection of rotavirus on polarized human intestinal epithelial (Caco-2) cells,” Journal of Virology, vol. 65, no. 8, pp. 4190–4197, 1991.
- D. A. Hume, “The many alternative faces of macrophage activation,” Frontiers in Immunology, vol. 6, article 370, 2015.
- D. A. Hume, “Macrophages as APC and the dendritic cell myth,” The Journal of Immunology, vol. 181, no. 9, pp. 5829–5835, 2008.
- J. Geginat, G. Nizzoli, M. Paroni et al., “Immunity to pathogens taught by specialized human dendritic cell subsets,” Frontiers in Immunology, vol. 6, article 527, 2015.
- R. M. Steinman, “The dendritic cell system and its role in immunogenicity,” Annual Review of Immunology, vol. 9, no. 1, pp. 271–296, 1991.
- N. L. Harris and F. Ronchese, “The role of B7 costimulation in T-cell immunity,” Immunology & Cell Biology, vol. 77, no. 4, pp. 304–311, 1999.
- V. Blazevic, C. M. Trubey, and G. M. Shearer, “Analysis of the costimulatory requirements for generating human virus-specific in vitro T helper and effector responses,” Journal of Clinical Immunology, vol. 21, no. 4, pp. 293–302, 2001.
- L. J. Berghaus, J. N. Moore, D. J. Hurley et al., “Innate immune responses of primary murine macrophage-lineage cells and RAW 264.7 cells to ligands of Toll-like receptors 2, 3, and 4,” Comparative Immunology, Microbiology and Infectious Diseases, vol. 33, no. 5, pp. 443–454, 2010.
- T. Abe, H. Takahashi, H. Hamazaki, N. Miyano-Kurosaki, Y. Matsuura, and H. Takaku, “Baculovirus induces an innate immune response and confers protection from lethal influenza virus infection in mice,” Journal of Immunology, vol. 171, no. 3, pp. 1133–1139, 2003.
- C. Istrate, I. Douagi, A. Charpilienne et al., “Bone marrow dendritic cells internalize live RF-81 bovine rotavirus and rotavirus-like particles (RF 2/6-GFP-VLP and RF 8∗2/6/7-VLP) but are only activated by live bovine rotavirus,” Scandinavian Journal of Immunology, vol. 65, no. 6, pp. 494–502, 2007.
- P. Stoitzner, M. Zanella, U. Ortner et al., “Migration of langerhans cells and dermal dendritic cells in skin organ cultures: augmentation by TNF-α and IL-1β,” Journal of Leukocyte Biology, vol. 66, no. 3, pp. 462–470, 1999.
- P. Rieckmann, J. M. Tuscano, and J. H. Kehrl, “Tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) in B-lymphocyte function,” Methods, vol. 11, no. 1, pp. 128–132, 1997.
- B.-G. Xiao, C.-Z. Lu, and H. Link, “Cell biology and clinical promise of G-CSF: immunomodulation and neuroprotection,” Journal of Cellular and Molecular Medicine, vol. 11, no. 6, pp. 1272–1290, 2007.
- S. Xu, M. Höglund, L. Hàkansson, and P. Venge, “Granulocyte colony-stimulating factor (G-CSF) induces the production of cytokines in vivo,” British Journal of Haematology, vol. 108, no. 4, pp. 848–853, 2000.
- J. Xu, Y. Yang, C. Wang, and B. Jiang, “Rotavirus and coxsackievirus infection activated different profiles of toll-like receptors and chemokines in intestinal epithelial cells,” Inflammation Research, vol. 58, no. 9, pp. 585–592, 2009.
- E. E. Rollo, K. P. Kumar, N. C. Reich et al., “The epithelial cell response to rotavirus infection,” Journal of Immunology, vol. 163, no. 8, pp. 4442–4452, 1999.
- I. Margine, L. Martinez-Gil, Y.-Y. Chou, and F. Krammer, “Residual baculovirus in insect cell-derived influenza virus-like particle preparations enhances immunogenicity,” PLoS ONE, vol. 7, no. 12, article e51559, 2012.
- T. Abe, H. Hemmi, H. Miyamoto et al., “Involvement of the Toll-like receptor 9 signaling pathway in the induction of innate immunity by baculovirus,” Journal of Virology, vol. 79, no. 5, pp. 2847–2858, 2005.
- E. M. Deal, K. Lahl, C. F. Narváez, E. C. Butcher, and H. B. Greenberg, “Plasmacytoid dendritic cells promote rotavirus-induced human and murine B cell responses,” The Journal of Clinical Investigation, vol. 123, no. 6, pp. 2464–2474, 2013.
- T. Fifis, A. Gamvrellis, B. Crimeen-Irwin et al., “Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors,” The Journal of Immunology, vol. 173, no. 5, pp. 3148–3154, 2004.
- S. Mayor and R. E. Pagano, “Pathways of clathrin-independent endocytosis,” Nature Reviews Molecular Cell Biology, vol. 8, no. 8, pp. 603–612, 2007.
- C. Reis E Sousa, P. D. Stahl, and J. M. Austyn, “Phagocytosis of antigens by Langerhans cells in vitro,” The Journal of Experimental Medicine, vol. 178, no. 2, pp. 509–519, 1993.
- F. Sallusto, M. Cella, C. Danieli, and A. Lanzavecchia, “Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products,” Journal of Experimental Medicine, vol. 182, no. 2, pp. 389–400, 1995.
- R. M. Steinman and J. Swanson, “The endocytic activity of dendritic cells,” The Journal of Experimental Medicine, vol. 182, no. 2, pp. 283–288, 1995.
- L. Pelkmans and A. Helenius, “Endocytosis via caveolae,” Traffic, vol. 3, no. 5, pp. 311–320, 2002.
- Z. Liu and P. A. Roche, “Macropinocytosis in phagocytes: regulation of MHC class-II-restricted antigen presentation in dendritic cells,” Frontiers in Physiology, vol. 6, article 1, 2015.
- M. K. Ghosh, E. Dériaud, M.-F. Saron et al., “Induction of protective antiviral cytotoxic T cells by a tubular structure capable of carrying large foreign sequences,” Vaccine, vol. 20, no. 9-10, pp. 1369–1377, 2002.
- D. Vercauteren, R. E. Vandenbroucke, A. T. Jones et al., “The use of inhibitors to study endocytic pathways of gene carriers: optimization and pitfalls,” Molecular Therapy, vol. 18, no. 3, pp. 561–569, 2010.
- V. M. Pietiäinen, V. Marjomäki, J. Heino, and T. Hyypiä, “Viral entry, lipid rafts and caveosomes,” Annals of Medicine, vol. 37, no. 6, pp. 394–403, 2005.
- L. A. Mulcahy, R. C. Pink, and D. R. Carter, “Routes and mechanisms of extracellular vesicle uptake,” Journal of Extracellular Vesicles, vol. 3, Article ID 24641, 2014.
- L. Buonaguro, M. L. Tornesello, M. Tagliamonte et al., “Baculovirus-derived human immunodeficiency virus type 1 virus-like particles activate dendritic cells and induce ex vivo T-cell responses,” Journal of Virology, vol. 80, no. 18, pp. 9134–9143, 2006.
Copyright © 2016 Maria Malm et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.